Aug 13, 2026 earnings call — Sales growth, margin expansion, cash generation
Q2 net sales were $17.8 million, an 11% increase year-over-year.
Revenue $0.0B (est $0.0B) · EPS $-0.34 (est $-0.23)
Key quotes
"We currently serve approximately 300 customers, including all 5 major U.S. dialysis providers, while also supplying products to more than 30 international markets."
"When we discuss our goal of achieving approximately 30% gross margins by 2029, that target is not based on a single initiative."
"This performance contributed to a quarter-end balance of $24.8 million in cash, cash equivalents, and investments available for sale."
Analyst Q&A 2
West Coast expansion and medical device plans
Q (Nicholas Sherwood · Maxim Group): He asked how West Coast expansion is progressing and how they are building operations there. He also asked about supply contract renewal terms and how the new medical device will fit with current products.
A: They said expanding in the West Coast is a strategic objective: they took over an existing West customer base and now supply those customers regularly, which opens opportunities to meet other clinics and should drive continued growth. Their standard supply agreements are approximately 3 years with set prices and typical price escalators, and they begin renewal discussions about 6 months before the end. On the medical device, they said the product folds into the current portfolio, targets a large opportunity, could make them potentially the only other supplier in the United States, and development will be funded from their balance sheet.
"We would be potentially the only other supplier of this type of product in the United States." — Mark Strobeck (CEO)
Product mix, margins, and West growth plan
Q (H.C. Wainwright): She asked whether product mix helps West Coast growth and reaching the high end of the 18% to 22% margin guide, and asked the plan to keep growing the Western business. She also asked if incremental volume margins will match corporate average or be diluted by freight and onboarding costs.
A: They said the Western business is skewed toward their liquid products, which have a higher margin profile and they are a leading manufacturer of those liquids. To grow the West they will educate dialysis centers, offer an alternative to the single provider many clinics use, and rely on current customer success to spread in the market. For the incremental volume seen over the quarter, they said it has been consistently higher than the corporate average.
"So for the incremental growth that we've seen over the quarter, that is consistently higher than the corporate average." — Mark Strobeck (CEO)